🔎 Trials Near Me

ホーム › 非小細胞肺癌 › カンザス州

カンザス州における非小細胞肺癌の臨床試験

カンザス州内の拠点で、非小細胞肺癌に関する34件の研究が参加者を募集しています。

カンザス州内の都市

公式研究テキスト（英語）

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • The University of Kansas Cancer Center - Olathe, Olathe
  • Cancer Center of Kansas - Pratt, Pratt
  • Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita
  • 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  • Ascension Via Christi Hospitals Wichita, Wichita
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07293247

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • HaysMed, Hays
  • Lawrence Memorial Hospital, Lawrence
  • The University of Kansas Cancer Center - Olathe, Olathe
  • 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

  • Kansas City Cancer Center /ID# 273679, Overland Park
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06772623

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • The University of Kansas Cancer Center, Westwood
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  • University of Kansas Cancer Center, Westwood
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05498428

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  • Research Site, Westwood
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06218914

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Saint Luke's South Hospital, Overland Park
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • University of Kansas Cancer Center, Fairway
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  • Research Site, Leawood
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06868277

Pan-tumor MRD Study

  • Cotton O'Neil Cancer Center [Stormont Vail], Topeka
  • Cancer Center of Kansas, Wichita
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/24更新 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • Central Care Cancer Center - Garden City, Garden City
  • Central Care Cancer Center - Great Bend, Great Bend
  • Mercy Hospital Pittsburg, Pittsburg
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT03191149

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  • Cancer Center of Kansas, Wichita
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06561386

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

  • University of Kansas, Westwood
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07020117

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • Local Institution - 007-942-B, Chanute
  • Local Institution - 007-942-D, El Dorado
  • Local Institution - 007-942-E, Independence
  • 他12件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT04613596

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • University of Kansas Medical Center /ID# 263196, Westwood
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06236438

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • The University of Kansas Cancer Center - Westwood, Westwood
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • University of Kansas Medical Center, Kansas City
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06343402

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Cancer Center-Overland Park, Overland Park
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06500481

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • The University of Kansas Cancer Center, Kansas City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • University of Kansas Medical Center (KUMC), Westwood
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • The University of Kansas Cancer Center, Investigational Drug Services, Fairway
  • The University of Kansas Clinical Research Center, Fairway
  • The University of Kansas Hospital, Kansas City
  • 他6件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  • University of Kansas Cancer Center, Westwood
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/25更新 · NCT06216301

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

  • The University of Kansas Cancer Center, Westwood
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/06/11更新 · NCT05361174

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • 他7件
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/03更新 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • 他7件
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • 他7件
被験者募集中第2相
18 Minutes · 全性別 · 2026/05/05更新 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • 他8件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/05/05更新 · NCT06616584

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • The University of Kansas Cancer Center, Fairway
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/18更新 · NCT06244771

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • HaysMed, Hays
  • Lawrence Memorial Hospital, Lawrence
  • The University of Kansas Cancer Center - Olathe, Olathe
  • 他6件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

  • The University of Kansas Cancer Center (KUCC), Fairway
  • The University of Kansas Cancer Center, Westwood Campus, Kansas City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/28更新 · NCT04467723

A Study of IBI363 in Subjects with Advanced Solid Malignancies

  • University of Kansas Medical Center (KUMC), Fairway
被験者募集中第2相
18歳以上 · 全性別 · 2024/12/19更新 · NCT06281678

Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

  • The University of Kansas Cancer Center, Westwood Campus, Kansas City
被験者募集中観察研究
18歳以上 · 全性別 · 2024/05/08更新 · NCT04680377

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

  • The University of Kansas Cancer Center (KUCC), Fairway
  • The University of Kansas Cancer Center, Westwood Campus, Kansas City
被験者募集中観察研究
18歳〜110歳 · 全性別 · 2024/02/23更新 · NCT05332925

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。